Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Curis | CRIS | Jul 29, 2024 | 6.05 | -1.14 |
Curtiss-Wright | CW | Jul 29, 2024 | 281.14 | +0.29 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Jul 29, 2024 | 42.47 | -0.12 |
Cushman & Wakefield | CWK | Jul 29, 2024 | 13.31 | -1.70 |
Custom Truck One Source | CTOS | Jul 29, 2024 | 5.02 | -2.90 |
Customers Bancorp | CUBI | Jul 29, 2024 | 63.51 | -5.00 |
Customers Bancorp E Pref | CUBI-E | Jul 29, 2024 | 25.68 | -0.15 |
Customers Bancorp F Pref | CUBI-F | Jul 29, 2024 | 25.53 | +0.31 |
Cutera | CUTR | Jul 29, 2024 | 1.40 | -7.89 |
CVB Financial | CVBF | Jul 29, 2024 | 19.05 | -4.94 |
CVD Equipment | CVV | Jul 29, 2024 | 3.97 | -0.25 |
CVR Energy | CVI | Jul 29, 2024 | 26.92 | -1.75 |
Cvr Partners LP Unit | UAN | Jul 29, 2024 | 77.40 | -1.33 |
CVRx | CVRX | Jul 29, 2024 | 9.27 | -3.54 |
CVS Health | CVS | Jul 29, 2024 | 61.57 | +0.93 |
CXApp A | CXAI | Jul 29, 2024 | 2.17 | -3.56 |
CyberArk Software | CYBR | Jul 29, 2024 | 258.45 | +0.30 |
Cybin | CYBN | Jul 29, 2024 | 0.29 | +0.59 |
Cyclacel Pharmaceuticals | CYCC | Jul 29, 2024 | 1.63 | -4.12 |
Cyclacel Pharmaceuticals Pref | CYCCP | Jul 29, 2024 | 10.00 | -1.96 |
Cyclerion Therapeutics | CYCN | Jul 29, 2024 | 3.34 | +7.05 |
Cyclo Therapeutics | CYTH | Jul 29, 2024 | 1.18 | +2.61 |
Cyngn | CYN | Jul 29, 2024 | 6.08 | -4.70 |
Cytek Biosciences | CTKB | Jul 29, 2024 | 6.37 | -5.35 |
Cytokinetics | CYTK | Jul 29, 2024 | 59.09 | -1.01 |
Cytomed Therapeutics | GDTC | Jul 29, 2024 | 1.70 | -6.08 |
CytomX Therapeutics | CTMX | Jul 29, 2024 | 1.42 | -5.33 |
Cytosorbents | CTSO | Jul 29, 2024 | 1.21 | +17.48 |
D-MARKET Electronic Services & Trading ADR | HEPS | Jul 29, 2024 | 3.13 | -1.26 |
D-Wave Quantum | QBTS | Jul 29, 2024 | 0.99 | -0.01 |
|
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.